You should know that CD163 only accounts for small population and they cannot suppress massive number of t-cells.
Merck makes the collaboration with Moderna look so real just like Merck signed the deal with Daiichi on three ADCs.See the comparison between Neoadjuvant PD1 inhibitor treatment and Moderna neoantigen therapy? Tell me which one has better results. Targeting for several neoantigens may have efficacy for a certain percentage of hot tumors. But it lacks of efficacy in treating cold tumors. If I am not mistaken, the trials between Merck and Moderna only target hot tumor.
Market Data 
Markets 
AI
